Juvenescence is a clinical-stage, AI-enabled biotech focused on developing novel medicines to extend healthy lifespan. Its approach centers on developing therapies that target core ageing mechanisms to treat and prevent age-related diseases. The company’s diverse pipeline includes clinical and near-clinical candidates addressing cognition, cardio-metabolism, immunity and cellular repair. Juvenescence also holds investments in a number of companies and platform technologies focused on AI and regenerative medicine. Led by CEO Dr Richard Marshall and founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan, the company is based in Ramsey, UK. In May 2025 it closed a $76M first tranche of a Series B-1 to advance its therapeutics into clinical development and enhance its core medicine pipeline.

Total raised

$76M

Funding rounds

1

Latest round

Series B

Latest activity

May 2025